Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics Inc (TVTX) is a biopharmaceutical innovator developing therapies for rare kidney, liver, and metabolic diseases. This page provides a comprehensive repository of official company announcements, clinical trial updates, and regulatory developments.
Investors and researchers will find curated press releases detailing milestones for pipeline candidates like FILSPARI and sparsentan, along with financial disclosures and partnership announcements. Content is organized to highlight material events including FDA communications, trial phase completions, and strategic collaborations.
All updates are sourced directly from Travere Therapeutics to ensure accuracy. Bookmark this page for efficient tracking of the company’s progress in advancing treatments for IgA nephropathy, FSGS, and other rare conditions.
Travere Therapeutics, Inc. (Nasdaq: TVTX) will present data on FILSPARI (sparsentan) at the National Kidney Foundation (NKF) Spring Clinical Meetings and the European Renal Association (ERA) Congress. The presentations showcase FILSPARI's efficacy over traditional treatments, highlighting its benefits in patients with IgA nephropathy.
Travere Therapeutics, Inc. (NASDAQ: TVTX) will be participating in upcoming investor conferences including the BofA Securities Health Care Conference on May 15, 2024, and the Jefferies Global Healthcare Conference on June 5, 2024. The live webcasts of the presentations can be accessed on Travere's website with replays available for 30 days after each event.
Travere Therapeutics reported strong financial results for the first quarter of 2024, showcasing significant growth and achievements in key regulatory milestones. The FDA granted Priority Review for converting FILSPARI to full approval for IgAN in the U.S., with a PDUFA target action date of September 5, 2024. European Commission granted conditional marketing authorization for FILSPARI in Europe. The Company dosed the first patients in the pivotal Phase 3 HARMONY Study and has cash, cash equivalents, and marketable securities totaling $441.0 million as of March 31, 2024.
Travere Therapeutics, Inc. (NASDAQ: TVTX) will report its first quarter 2024 financial results on May 6, 2024. The company will host a conference call and webcast to discuss the results and provide a business update. Details can be accessed on Travere's Investor page.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
